Volociximab
Volociximab (M200) is a chimeric human/murine IgG4 antibody IIA1 targeting integrin α5β1 (EC50=0.2 nM) . Integrin α5β1 is a major fibronectin receptor involved in angiogenesis. Volociximab has antiangiogenic and antitumor activities and inhibits the proliferation of human umbilical vein vascular endothelial cells (HUVECs) [1][2].
Product Specifications
CAS Number
[558480-40-3]
Product Name Alternative
M200; Eos 200-4
UNSPSC
12352203
Target
Integrin
Type
Inhibitory Antibodies
Related Pathways
Cytoskeleton
Applications
Cancer-programmed cell death
Field of Research
Cancer; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/volociximab.html
Purity
99.96
Solubility
10 mM in DMSO
Smiles
[Volociximab]
Molecular Weight
(145.5 kDa)
References & Citations
[1]Bhaskar V, et al. Volociximab, a chimeric integrin alpha5beta1 antibody, inhibits the growth of VX2 tumors in rabbits. Invest New Drugs. 2008 Feb;26 (1) :7-12. |[2]Ramakrishnan V, et al. Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent. J Exp Ther Oncol. 2006;5 (4) :273-86.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Isoform
α5β1
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
021633 1 mg
3',5'-O-[Tetrakis (1-methylethyl) -1,3-disiloxanediyl]guanosine-13C,15N2
Ask
View Details 